Tag Archives: medical devices directive 93/42/EC

Draft Guidance Published by Drug Regulators on CE-marked Medical Devices – Neurostimulators

Drug Regulators, MHRA, Publish Draft Guidance on the Vigilance System for CE-marked devices – Neurostimulators.

A full copy is available here.

Introduction

This guidance sets out the Medicines and Healthcare products Regulatory Agency’s (MHRA) views on the interpretation of the Medical Devices Regulations.

Why Report

To obtain information on device related incidents, the Medical Devices Directive requires manufacturers to have procedures in place for systematic review of experience gained from device usage in the post-production phase.

What Should Be Reported

The Medical Devices Directive, through the relevant national regulations [4], requires manufacturers to notify the relevant competent authority (the MHRA in the UK) if:

  • They know of any deterioration or malfunction of a neurostimulator, or any inadequacy in the instructions for use which has led, or might lead, to a serious deterioration in the state of health.
  • The neurostimulator has been subject to a Field Safety Corrective Action

Periodic Summary Reporting

Some adverse incidents are appropriate for periodic summary reporting:

  • lead fracture
  • lead shorts
  • lead migration
  • high lead impedance
  • electromagnetic interference

Adverse event trending

Some adverse incidents are expected and foreseeable, and as a result may be considered not routinely reportable. These must all be clearly identified in the manufacturer’s labelling, clinically well recognised and quantifiably predictable, well documented in the device master record with an appropriate risk assessment, and clinically acceptable in terms of individual patient benefit.

    If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

    Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

    ida 100programme 515x64 LowRes Draft Guidance Published by Drug Regulators on CE marked Medical Devices   Neurostimulators

    Turn your Business Into an Investor Magnet

    How to Write a Business Plan – Free E-Course

    Get the secrets that turns your project into an investment magnet, 100% of our clients raise the finance they need to take their projects to the next stage, we will share these secrets with you. – Sign up for Free

    Grow your Expertise for Free

    As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

    First name

    E-mail address

    This guideline ap
    recombinant vaccines for the prevention and treatment of infectious disease, and provides guidance on quality, non-clinical and clinical aspects.
    ida consultants freestrategyconsultation 515x64 Draft Guidance Published by Drug Regulators on CE marked Medical Devices   Neurostimulators